Alice Melao,  —

A rare type of cancer called histiocytic sarcoma may trigger the development of cold agglutinin hemolytic anemia, a recent case suggests. This malignant cancer, which arises from the transformation of some immune cells present in the connective tissue, should be considered as a secondary cause of cold agglutinin hemolytic…

Treatment with the anti-PD-1 targeted checkpoint inhibitor Keytruda (pembrolizumab) was found to trigger autoimmune hemolytic anemia (AIHA) in a man with non-small cell lung cancer (NSCLC). The case was described in the study, “Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung…

Apellis Pharmaceuticals and SFJ Pharmaceuticals are now collaborating on the development of investigational therapy APL-2 as a treatment for cold agglutinin disease (CAD) and warm antibody hemolytic anemia (wAIHA). This follows the announcement of a newly established partnership to support the clinical program of APL-2 for the treatment…

Treatment with the anti-cancer immune checkpoint inhibitor Tecentriq (atezolizumab) can cause cold agglutinin disease (CAD), a case report shows. The case was described in a letter to the editor, “Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s…

A case of simultaneous cryoglobulinemic vasculitis and cold agglutinin disease (CAD) was reported for the first time in a patient, according to Chinese researchers. The rare occurrence was described in the study, “Concomitant cryoglobulinemic vasculitis and cold agglutinin disease successfully treated with bortezomib: A case report,”…

Treatment with low-dose Rituxan can effectively treat patients with warm autoimmune hemolytic anemia (wAIHA) but higher doses may be more beneficial for patients with cold agglutinin disease (CAD), results from a 10-year retrospective study suggest. The study, “Low dose rituximab in autoimmune hemolytic anemia: ten years…

Acute kidney injury triggered by excessive alcohol intake was described for the first time by Japanese researchers in a patient with cold agglutinin disease (CAD). The case was reported in the study “Acute Kidney Injury by Renal Hemosiderosis Secondary to Primary…

Treatment with Soliris (eculizumab, marketed by Alexion) can effectively reverse cold agglutinin disease (CAD) attacks and induce rapid clinical remission, a case report shows. The study, “High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold…